Developing Translational Proteomics For The Next Human Health Stage
Developing Translational Proteomics For The Next Human Health Stage
Range Biotechnologies is a company developing translational proteomics (proteins) for the next stage of human health. Pulse 2.0 interviewed Range Biotechnologies co-founder and CEO Brandon Wilson, Ph.D., to learn more.
Powering precision medicine with proteomics
Longevity.Technology: Proteomics, the study of proteins in the body, has long been touted for its potential to help develop more effective ways to diagnose, treat and prevent diseases, but the field to date has largely focused on the discovery of protein biomarkers. Range Bio is founded on the belief that a significant impact on human health can only be realized if biomarker discovery is complemented by scalable, targeted quantification of proteins. We caught up with the company’s CEO Dr Brandon Wilson and CTO Dr Nicolo Maganzini to find out more.
Powering precision medicine with proteomics
Longevity.Technology: Proteomics, the study of proteins in the body, has long been touted for its potential to help develop more effective ways to diagnose, treat and prevent diseases, but the field to date has largely focused on the discovery of protein biomarkers. Range Bio is founded on the belief that a significant impact on human health can only be realized if biomarker discovery is complemented by scalable, targeted quantification of proteins. We caught up with the company’s CEO Dr Brandon Wilson and CTO Dr Nicolo Maganzini to find out more.
Seed Round Announcement
With the Potential to Revolutionize Personalized Health, Range Biotechnologies Receives $5.2 Million in Seed Funding Led by TechBio-Focused ARTIS Ventures. Range Bio seeks to enable better diagnostics and faster drug development by unlocking translational proteomics
Seed Round Announcement
With the Potential to Revolutionize Personalized Health, Range Biotechnologies Receives $5.2 Million in Seed Funding Led by TechBio-Focused ARTIS Ventures. Range Bio seeks to enable better diagnostics and faster drug development by unlocking translational proteomics
Artis Ventures' Bet on Protein-Research Technology
Brian Gormley of The Wall Street Journal spoke with ARTIS Partner Ameena El-Bibany to discuss their portfolio companies in the field of protein research, including Range Biotechnologies and Glyphic Biotechnologies. #techbio #biotech #proteinresearch
Artis Ventures' Bet on Protein-Research Technology
Brian Gormley of The Wall Street Journal spoke with ARTIS Partner Ameena El-Bibany to discuss their portfolio companies in the field of protein research, including Range Biotechnologies and Glyphic Biotechnologies. #techbio #biotech #proteinresearch
Proteomics moves toward the clinic
Proteomics moves toward the clinic
Broad researchers are showing how protein analysis is not just a scientific tool but could also help improve patient care.
Many of our proteins remain hidden in the dark proteome
Many of our proteins remain hidden in the dark proteome
Scientists want to develop new tools and methods to uncover the proteins they’ve yet to see